Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03884556
Title TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tizona Therapeutics, Inc
Indications

lymphoma

Advanced Solid Tumor

Therapies

Gemcitabine + Nab-paclitaxel + TTX-030

Docetaxel + TTX-030

Pembrolizumab + TTX-030

TTX-030

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.